These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18457727)

  • 1. [Imatinib-induced DRESS].
    Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
    Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
    Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
    Sugito M; Tsukada J; Higashi T; Ohta T; Matsuura A; Kubota A; Mizobe T; Mouri F; Morimoto H; Tanaka Y
    Rinsho Ketsueki; 2005 Nov; 46(11):1226-8. PubMed ID: 16440809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Livedoid skin reaction probably due to imatinib therapy.
    Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E
    Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
    Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
    Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
    Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desensitization to imatinib in patients with leukemia.
    Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.
    Wahiduzzaman M; Pubalan M
    Dermatol Online J; 2008 Dec; 14(12):14. PubMed ID: 19265627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
    Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
    Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible sensorineural hearing loss due to Imatinib.
    Attili VS; Bapsy PP; Anupama G; Lokanatha D
    Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imatinib-induced purpuric vasculitis].
    Hamm M; Touraud JP; Mannone L; Klisnick J; Ponnelle T; Lambert D
    Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):765-7. PubMed ID: 14576606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Busuttil DP
    Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
    Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
    Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
    de Masson A; Bouvresse S; Clérici T; Mahé E; Saïag P
    Ann Dermatol Venereol; 2011 Feb; 138(2):135-9. PubMed ID: 21333826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.